Intra-Cellular Therapies, Inc.
ITCINext catalyst
ITI-1284
Agitation Associated With Alzheimer's Dementia
Get an email about ITCI's next catalysts
Track Intra-Cellular Therapies (ITCI) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 4 more upcoming events in our data (Phase 3 readout, Phase 2 readout).See the timeline
5 upcoming, 0 past
ITI-1284 Phase 2 Est. Readout
Primary completion for ITI-1284 trial (NCT06480383) in Generalized Anxiety Disorder
SourceLumateperone Phase 3 Est. Readout
Primary completion for Lumateperone trial (NCT06372964) in Bipolar Depression
SourceLumateperone low dose Phase 3 Est. Readout
Primary completion for Lumateperone low dose trial (NCT06690398) in Irritability Associated With Autism Spectrum Disorder
SourceLumateperone high dose Phase 3 Est. Readout
Estimated primary completion for Lumateperone high dose trial (NCT06706674) in Irritability Associated With Autism Spectrum Disorder. Topline data typically follows completion by weeks to months.
SourceITI-1284 Phase 2 Est. Readout
Primary completion for ITI-1284 trial (NCT06701903) in Generalized Anxiety Disorder
SourceMarket Overview
Stock performance and key metrics
ITI-1284
Agitation Associated With Alzheimer's Dementia
JNJ-99245354
Generalized Anxiety Disorder
ITI-007
Schizophrenia
Lumateperone high dose
Irritability Associated With Autism Spectrum Disorder
Lumateperone
Major Depressive Disorder
Lumateperone low dose
Irritability Associated With Autism Spectrum Disorder
ITI-007 (Lumateperone)
Bipolar Depression
Lumateperone (ITI-007)
Bipolar Depression
Risperidone
Schizophrenia
Lenrispodun
Parkinson Disease
ITI-214
Heart Failure, Systolic
Caplyta
Borderline Personality Disorder
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ITI-1284 | Phase 3 | Agitation Associated With Alzheimer's Dementia | - | - |
JNJ-99245354 | Phase 3 | Generalized Anxiety Disorder | - | - |
ITI-007 | Phase 3 | Schizophrenia | - | - |
Lumateperone high dose | Phase 3 | Irritability Associated With Autism Spectrum Disorder | - | - |
Lumateperone | Phase 3 | Major Depressive Disorder | - | - |
Lumateperone low dose | Phase 3 | Irritability Associated With Autism Spectrum Disorder | - | - |
ITI-007 (Lumateperone) | Phase 3 | Bipolar Depression | - | - |
Lumateperone (ITI-007) | Phase 3 | Bipolar Depression | - | - |
Risperidone | Phase 2 | Schizophrenia | - | - |
Lenrispodun | Phase 2 | Parkinson Disease | - | - |
ITI-214 | Phase 2 | Heart Failure, Systolic | - | - |
Caplyta | Phase 2 | Borderline Personality Disorder | - | - |
Bipolar Depression
3 drugs in this indication
Generalized Anxiety Disorder
2 drugs in this indication
Schizophrenia
2 drugs in this indication
Irritability Associated With Autism Spectrum Disorder
2 drugs in this indication
Major Depressive Disorder
1 drug in this indication
Heart Failure, Systolic
1 drug in this indication
Agitation Associated With Alzheimer's Dementia
1 drug in this indication
Parkinson Disease
1 drug in this indication
Psychosis Associated With Alzheimer's Disease
1 drug in this indication
Magnesium transport
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Intra-Cellular Therapies, Inc.'s drug pipeline?→
CatalystAlert tracks 12 drug candidates in Intra-Cellular Therapies, Inc.'s (ITCI) pipeline across Phase 3, Phase 2. Its lead program is ITI-1284 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Intra-Cellular Therapies, Inc.'s next FDA catalyst?→
Intra-Cellular Therapies, Inc.'s (ITCI) next tracked catalyst is a Phase 2 readout expected March 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ITCI biotech catalysts?→
Add ITCI to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Intra-Cellular Therapies, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.
